FY23. To 11 - CTN-0145: standard versus high dose ED-initiated buprenorphine induction. POP: 8/28/23 - 8/27/24.
Active Awarded Last action
- Contract number
- 75N95023F00004
- Awardee
-
The Emmes Company, LLC UEI NBQCBJ6FXBU4
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,036,687
Award facts
- Opportunity
-
- 75N95023F00004 Solicitation number
- Contract value 100% obligated
- $1,036,687.00 Current and potential, with all options
- Completion date 79% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Rockville, MD 20850, USA
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $270,761 | |
| Exercise an Option | $267,558 | |
| Exercise an Option | $256,829 | |
| Original award | $241,539 |
About this award
The National Institute on Drug Abuse awarded a delivery order valued at $1.04 million to The Emmes Company, LLC for Task Order 11 under the Clinical Trials Network Clinical Coordinating Center contract. This delivery order supports a clinical research study titled "Standard Versus High Dose ED-Initiated Buprenorphine Induction," with a performance period running from August 28, 2023 through August 27, 2024. The contract utilizes a cost-plus-fixed-fee pricing structure and does not include any set-aside designation, indicating competitive award to this established federal contractor. Work will be performed at Emmes' headquarters in Rockville, Maryland.
The Emmes Company, LLC is a prominent clinical research organization specializing in comprehensive research support services for federal agencies, particularly NIH institutes. As the Clinical Coordinating Center for NIDA's Clinical Trials Network, Emmes provides critical infrastructure including biostatistical analysis, data management, clinical trial coordination, and regulatory support for complex biomedical research initiatives. This delivery order represents one of multiple task orders executed under Emmes' larger $49.5 million Clinical Coordinating Center IDV contract with NIDA, enabling the company to rapidly deploy resources across diverse substance abuse research programs. The study examining buprenorphine induction protocols aligns with NIDA's mission to advance evidence-based treatment approaches for opioid use disorder.
Quick answers
Who was awarded contract 75N95023F00004?
75N95023F00004 was awarded to The Emmes Company, LLC by National Institute on Drug Abuse (National Institutes of Health) on August 28, 2023.
How much is contract 75N95023F00004 worth?
The government has obligated $1,036,687 on 75N95023F00004.
Is contract 75N95023F00004 an order under another contract?
Yes. 75N95023F00004 is a delivery order under 75N95020D00012, an indefinite delivery contract.
Was contract 75N95023F00004 competed?
The extent of competition for 75N95023F00004 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award